{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:45:25Z","timestamp":1742399125434},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/rhu.0b013e318164dceb","type":"journal-article","created":{"date-parts":[[2008,5,5]],"date-time":"2008-05-05T08:07:20Z","timestamp":1209974840000},"page":"6-11","source":"Crossref","is-referenced-by-count":20,"title":["Higher Therapeutic Plasma Oxypurinol Concentrations Might Be Required for Gouty Patients With Chronic Kidney Disease"],"prefix":"10.1097","volume":"14","author":[{"given":"Duangchit","family":"Panomvana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siriluk","family":"Sripradit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungchai","family":"Angthararak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210207","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"Drug therapy: the management of gout.","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Eng J Med"},{"key":"R2-2-20210207","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1001\/jama.289.21.2857","article-title":"Gout.","volume":"289","author":"Rott","year":"2003","journal-title":"JAMA"},{"key":"R3-2-20210207","first-page":"3543","article-title":"AHFS Drug Information.","author":"Mcevoy","year":"2001"},{"key":"R4-2-20210207","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review.","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R5-2-20210207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R6-2-20210207","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.1780310318","article-title":"Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol.","volume":"31","author":"Emmerson","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R7-2-20210207","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout.","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R8-2-20210207","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1445-5994.2000.tb00857.x","article-title":"The optimal use of allopurinol: an audit of allopurinol in South Auckland.","volume":"30","author":"Stamp","year":"2000","journal-title":"Aust NZ J Med"},{"key":"R9-2-20210207","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00124743-200010000-00006","article-title":"Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout.","volume":"6","author":"Vazquez-Mellado","year":"2000","journal-title":"J Clin Rheumatol"},{"key":"R10-2-20210207","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.rhu.0000164822.98163.22","article-title":"Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity.","volume":"11","author":"Perez-Ruiz","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"R11-2-20210207","first-page":"317","article-title":"A survey of allopurinol dosage prescribing.","volume":"15","author":"McClintock","year":"1994","journal-title":"NZ Med J"},{"key":"R12-2-20210207","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1445-5994.1976.tb04001.x","article-title":"Drug induced interstitial mephritis, hepatitis and exfoliative dermatitis.","volume":"6","author":"Mcmenamin","year":"1976","journal-title":"Aust NZ J Med"},{"key":"R13-2-20210207","first-page":"842","article-title":"Plasma oxypurinol concentration in patient with allopurinol hypersensitivity.","volume":"16","author":"Puig","year":"1989","journal-title":"Rheumatology"},{"key":"R14-2-20210207","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-86-2-196","article-title":"Allopurinol induced interstitial nephritis.","volume":"86","author":"Gelbart","year":"1977","journal-title":"Ann Int Med"},{"key":"R15-2-20210207","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-198611050-00001","article-title":"Clinical pharmacokinetics of allopurinol.","volume":"11","author":"Merrell","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"R16-2-20210207","first-page":"148","article-title":"Bioequivalence of allopurinol-containing tablet preparations.","volume":"37","author":"Barthel","year":"1999","journal-title":"Int J Clin Pharm Ther"},{"key":"R17-2-20210207","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2710.2003.00488.x","article-title":"Facike and rapid high-performance chromatography method for simultaneous determination of allopurinol and oxypurinol in human serum.","volume":"28","author":"Tada","year":"2003","journal-title":"J Clin Pharm Ther"},{"key":"R18-2-20210207","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.1988.tb03401.x","article-title":"Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate cxcretion.","volume":"26","author":"Day","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"R19-2-20210207","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0378-4347(00)82068-X","article-title":"High performance liquid chromatographic assay for allopurinol and oxypurinol in human plasma.","volume":"162","author":"Kramer","year":"1979","journal-title":"J Chromatogr"},{"key":"R20-2-20210207","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00315424","article-title":"Dosage prescribing and plasma oxypurinol levels in patients receiving allopurinol therapy.","volume":"39","author":"Peterson","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"R21-2-20210207","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","article-title":"Plasma oxypurinol concentrations during allopurinol therapy.","volume":"26","author":"Emmerson","year":"1987","journal-title":"Br J Rheumatol"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e318164dceb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:54:08Z","timestamp":1620971648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-200802000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e318164dceb","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}